NEWS

Poredeen Appoints ICB as Exclusive Named Patient ProgramManager for HMTM# in Hong Kong and Macau

“Making TauRx’s groundbreaking drug HMTM# accessible
to patients with Alzheimer's Disease under Named Patient Program”

Learn More

Immuno Cure Completed US$12M First Close of Series A Financing, led by AEF GBA Fund managed by Gobi Partners GBA

Closed the US$12 million tranche in the US$27 million Series A fundraising round. Led by the AEF Greater Bay Area Fund that Gobi Partners GBA manages, this round will be used to accelerate the development of DNA vaccines and antibodies, as well as to prepare for an initial public offering (“IPO”) in Hong Kong.

Learn More

Immuno Cure Kicks off Phase IIa Clinical Trial in Hong Kong

The initiation of a Phase IIa clinical trial of ICCOV, a COVID-19 DNA vaccine candidate. The clinical trial is initiated by Immuno Cure in collaboration with the University of Hong Kong (“HKU”) and will be conducted in Gleneagles Hospital Hong Kong.

 

Learn More

Immuno Cure kick off Phase I Clinical Trial in Shenzhen

A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS 

Learn More

Immuno Cure appoints new CFO

Strengthening of executive management team to propel growth strategy

Learn More

Immuno Cure secured maximum subsidy from HKSTP

Significant funding support for HIV Vaccine Clinical Trial

Learn More